Study to Screen for Psycho-sexual Health Disordersand Measure Neurochemical Correlation in Survivors of Gynaecological Cancers.
Phase 2
- Conditions
- Health Condition 1: N879- Dysplasia of cervix uteri, unspecified
- Registration Number
- CTRI/2022/02/040308
- Lead Sponsor
- AIIMS Intramural Interdepartmental Grant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age more than 18 years.
2. Those who are seeking treatment at the department of gynaecology and obstetrics/radiation oncology for gynaecological cancer.
3. Gynaecological cancer survivors i.e. cervical,
uterine, ovarian (including fallopian tube and
peritoneal), vaginal.
4. Willing to participate in the study and provide
written informed consent.
Exclusion Criteria
1. Those who are suffering from any communication
disability due to which they cannot be interviewed
for the purpose of the study.
2. Diagnosed cases of psychiatric illness before
diagnosis of malignancy.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome measure: <br/ ><br>1. Prevalence of depression in gynecological cancer survivors. <br/ ><br>2. Prevalence of anxiety in gynecological cancer survivors. <br/ ><br>3. Prevalence of psychological stress in gynecological cancer survivors. <br/ ><br>4. Prevalence of sexual dysfunction in gynecological cancer survivors. <br/ ><br>5. Prevalence of psychoactive substance use in gynecological cancer survivors. <br/ ><br>6. Serum Substance P, BDNF, and Neuropeptide Y levels in gynecological cancer <br/ ><br>survivors and correlation of levels with other primary outcome measures.Timepoint: two to twenty-three months.
- Secondary Outcome Measures
Name Time Method Secondary outcome measures: <br/ ><br>1. Risk factors associated with sexual dysfunction in gynaecological cancer survivors. <br/ ><br>2. Risk factors associated with depression, anxiety and psychoactive substance use in <br/ ><br>gynaecological cancer survivors. <br/ ><br>3. Correlation of serum Substance P, BDNF and Neuropeptide Y levels in <br/ ><br>gynaecological cancer survivors with degree of depression, anxiety, stress, sexual dysfunction and psychoactive substance use in gynaecological cancer survivors.Timepoint: two to twenty-three months.